CARISMA THERAPEUTICS
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strong cellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease. Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania.
CARISMA THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Medical Therapeutics
Founded:
2016-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.carismatx.com
Total Employee:
11+
Status:
Active
Contact:
484-899-0326
Total Funding:
121.85 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apache Euro Google Maps US Privacy User Signal Mechanism Google Maps API AdBlock Acceptable Ads Google Maps Embed
Similar Organizations
Juno Therapeutics
Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Saar Gill Co-Founder @ Carisma Therapeutics
Co-Founder
2016-01-01
Steven Kelly President & Chief Executive Officer @ Carisma Therapeutics
President & Chief Executive Officer
2018-02-01
Bruce A. Peacock Executive Chairman @ Carisma Therapeutics
Executive Chairman
Tom Wilton CBO @ Carisma Therapeutics
CBO
Debora Barton CMO @ Carisma Therapeutics
CMO
Daniel Cushing CTO & CDO @ Carisma Therapeutics
CTO & CDO
Michael Klichinsky Co-Founder and Chief Scientific Officer @ Carisma Therapeutics
Co-Founder and Chief Scientific Officer
2022-04-01
Jacob Gunterberg Director @ Carisma Therapeutics
Director
2018-06-01
Kenneth Locke VP, Manufacturing @ Carisma Therapeutics
VP, Manufacturing
2020-06-01
Founder
Investors List
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series B - Carisma Therapeutics
IP Group
IP Group investment in Series B - Carisma Therapeutics
HealthCap
HealthCap investment in Series B - Carisma Therapeutics
Agent Capital
Agent Capital investment in Series B - Carisma Therapeutics
Wellington Partners
Wellington Partners investment in Series B - Carisma Therapeutics
Penn Medicine Co-Investment Program
Penn Medicine Co-Investment Program investment in Series B - Carisma Therapeutics
Livzon Pharmaceutical Group
Livzon Pharmaceutical Group investment in Series B - Carisma Therapeutics
4BIO Capital
4BIO Capital investment in Series B - Carisma Therapeutics
Solasta Ventures
Solasta Ventures investment in Series B - Carisma Therapeutics
SymBiosis LLC
SymBiosis LLC investment in Series B - Carisma Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-25 | Carisma Therapeutics Announces Appointment Of Michael Klichinsky, PharmD, PhD, As Chief Scientific Officer |
Official Site Inspections
http://www.carismatx.com Semrush global rank: 7.81 M Semrush visits lastest month: 437
- Host name: cloudproxy10062.sucuri.net
- IP address: 192.124.249.62
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Carisma Therapeutics"
CAR-M Therapy | CAR-Macrophages - Carisma
Dedication to innovation. With decades of experience in biotechnology and pharma, our dedicated team of top scientists and industry leaders are focused on developing a differentiated kind of …See details»
Our Leadership - Carisma
Eugene Kennedy, MD. Eugene Kennedy joined Carisma in April 2024. He brings over 15 years of clinical and industry experience, including cross-functional leadership driving clinical …See details»
Carisma Therapeutics - Crunchbase Company Profile
Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in …See details»
Novartis signs initial agreement with Carisma Therapeutics for the ...
Mar 10, 2022 Carisma (www.carismatx.com) is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered …See details»
Carisma Therapeutics - LinkedIn
Carisma Therapeutics | 14,642 followers on LinkedIn. Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors | Carisma Therapeutics Inc. is a clinical stage …See details»
Working At Carisma Therapeutics: Company Overview and Culture …
Carismatx.com. Organization Type. Private. CEO. Steven Kelly. Social Media. Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid …See details»
Carisma Therapeutics Company Profile 2024: Stock ... - PitchBook
Carisma Therapeutics General Information Description. CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen …See details»
CARISMA Therapeutics - Overview, News & Similar companies
Aug 8, 2024 CARISMA Therapeutics contact info: Phone number: (267) 491-6422 Website: www.carismatx.com What does CARISMA Therapeutics do? Carisma Therapeutics Inc. is a …See details»
Moderna and Carisma Establish Collaboration to Develop in vivo ...
Jan 10, 2022 For more information, please visit www.carismatx.com. Moderna Forward-Looking Statements. This press release contains forward-looking statements within the meaning of the …See details»
Board of Directors | Scientific Advisory Board - Carisma
He had graduate training in immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland in 1978 and 1979, and post-doctoral training in …See details»
Carisma Therapeutics Announces Changes to its Board of Directors
Oct 30, 2024 Appointment of Sohanya Cheng. Resignation of Michael Torok. PHILADELPHIA, Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the …See details»
Carisma Therapeutics Announces Changes to its Board of Directors
Jul 1, 2024 Appointment of David Scadden, M.D. and Marella Thorell . Resignation of Regina Hodits and Björn Odlander. PHILADELPHIA, July 1, 2024 /PRNewswire/ -- Carisma …See details»
Carisma Therapeutics to Present New Data at the American …
Apr 22, 2024 Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative …See details»
Carisma and Moderna Expand Collaboration to Develop Two
Sep 10, 2024 For more information, please visit www.carismatx.com. Cautionary Note on Forward-Looking Statements. Statements in this press release about future expectations, …See details»
Contact Us - Carisma
This field is for validation purposes and should be left unchanged. Carisma Therapeutics Inc. 3675 Market St., Ste. 401 Philadelphia, PA 19104See details»
News Release Details - Carisma Therapeutics Inc.
Apr 25, 2022 - Klichinsky, co-founder of Carisma Therapeutics, co-invented the company's proprietary and first-of-its-kind engineered macrophage platform . PHILADELPHIA, April 25, …See details»
News Release Details - Carisma Therapeutics Inc.
PHILADELPHIA, May 26, 2022 /PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative …See details»
CAR-Macrophage Technology | Cell Therapy - Carisma
A tunable cell therapy platform. Carisma’s engineered cell therapies rest on breakthrough platform technology that enables genetic manipulation of myeloid cells (including monocytes and …See details»
Cancer Therapy Pipeline | Clinical Trials - Carisma
Developing therapies for a wide range of cancers. Carisma is building a pipeline with an initial focus in oncology aiming to bring the power of cellular immunotherapy to the large number of …See details»